[1] Holtfreter B, Albandar JM, Dietrich T, et al.Standards for reporting chronic periodontitis prevalence and severity in epidemiologic studies: Proposed standards from the Joint EU/USA Periodontal Epidemiology Working Group[J]. J Clin Periodontol, 2015, 42(5): 407-412. [2] Page RC.The etiology and pathogenesis of periodontitis[J]. Compend Contin Educ Dent, 2002, 23(5 Suppl): 11-14. [3] Koran K, Löe H.The role of local factors in the etiology of periodontal diseases[J]. Periodontol 2000, 1993, 2: 83-97. [4] Socransky SS, Haffajee AD.The bacterial etiology of destructive periodontal disease: current concepts[J]. J Periodontol,1992, 63(4 Suppl): 322-331. [5] Quirynen M, Teughels W, van Steenberghe D, et al. Microbial shifts after subgingival debridement and formation of bacterial resistance when combined with local or systemic antimicrobials[J]. Oral Dis, 2003, 9(Suppl 1): 30-37. [6] Lindhe J, Nyman S.The effect of plaque control and surgical pocket elimination on the establishment and maintenance of periodontal health. A longitudinal study of periodontal therapy in cases of advanced disease[J]. J Clin Periodontol, 1975, 2(2): 67-79. [7] Ramfjord SP, Caffesse RG, Morrison EC, et al.Four modalities of periodontal treatment compared over five years[J]. J Periodontal Res, 1987, 22(3): 222-223. [8] Hill R, Ramfjord S, Morrison E, et al.Four types of periodontal treatment compared over two years[J]. J Periodontol, 1981, 52(11): 655-662. [9] Winkel EG, Van Winkelhoff AJ, Timmerman MF, et al.Effects of metronidazole in patients with "refractory" periodontitis associated with Bacteroides forsythus[J]. J Clin Periodontol, 1997, 24(8): 573-579. [10] Renvert S, Wikström M, Dahlén G, et al.On the inability of root debridement and periodontal surgery to eliminate Actinobacillus actinomycetemcomitans from periodontal pockets[J]. J Clin Periodontol, 1990, 17(6): 351-355. [11] Gordon JM, Walker CB.Current status of systemic antibiotic usage in destructive periodontal disease[J]. J Periodontol, 1993, 64(Suppl 8S): 760-771. [12] Greenwell H.Position paper: Guidelines for periodontal therapy[J]. J Periodontol, 2001, 72(11): 1624-1628. [13] Steinberg D, Friedman M, Soskolne A, et al.A new degradable controlled release device for treatment of periodontal disease: in vitro release study[J]. J Periodontol, 1990, 61(7): 393-398. [14] Goodson J, Haffajee A, Socransky S.Periodontal therapy by local delivery of tetracycline[J]. J Clin Periodontol, 1979, 6(2): 83-92. [15] Jorgensen MG, Slots J.Responsible use of antimicrobials in periodontics[J]. J Calif Dent Assoc, 2000, 28(3): 185-193. [16] Greenstein G.Clinical significance of bacterial resistance to tetracyclines in the treatment of periodontal diseases[J]. J Periodontol, 1995, 66(11): 925-932. [17] Soskolne WA.Subgingival delivery of therapeutic agents in the treatment of periodontal diseases[J]. Crit Rev Oral Biol Med, 1997, 8(2): 164-174. [18] Poliak MS.Content of monomycin in bile and its effectiveness in inflammatory diseases and surgery of the biliary tract[J]. Antibiotiki, 1963, 8: 83-87. [19] Zuckerman JM.Macrolides and ketolides: azithromycin, clarithromycin, telithromycin[J]. Infect Dis Clin North Am, 2004, 18(3): 621-649. [20] Gluzman IS.Erythromycin ointment therapy of inflammatory diseases of eyelid,conjunctiva and cornea(Clinico-Experimental Studies)[J]. Oftalmol Zh, 1964, 19: 450-454. [21] Amsden GW.Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?[J]. J Antimicrob Chemother, 2005, 55(1): 10-21. [22] Moore PA.Dental therapeutic indications for the newer long-acting macrolide antibiotics[J]. J Am Dent Assoc, 1999, 130(9): 1341-1343. [23] Agarwal E, Bajaj P, Naik SB, et al.Locally delivered 0.5% azithromycin as an adjunct to non-surgical treatment in patients with chronic periodontitis with type 2 diabetes: a randomized controlled clinical trial[J]. J Periodontol, 2012, 88(12): 1281-1287. [24] Agarwal E, Pradeep AR, Bajaj P, et al.Efficacy of local drug delivery of 0.5% clarithromycin gel as an adjunct to non-surgical periodontal therapy in the treatment of current smokers with chronic periodontitis: a randomized controlled clinical trial[J]. J Periodontol, 2012, 83(9): 1155-1163. [25] Bajaj P, Pradeep AR, Agarwal E, et al.Locally delivered 0.5% clarithromycin, as an adjunct to nonsurgical treatment in chronic periodontitis with well-controlled type 2 diabetes: a randomized controlled clinical trial[J]. J Investig Clin Dent, 2012, 3(4): 276-283. [26] Kathariya R, Pradeep AR, Raghavendra NM, et al.Evaluation of subgingivally delivered 0.5% clarithromycin as an adjunct to nonsurgical mechanotherapy in the management of chronic periodontitis: a short-term double blinded randomized control trial[J]. J Investig Clin Dent, 2014, 5(1): 23-31. [27] Pradeep AR, Sagar SV, Daisy H, et al.Clinical and microbiologic effects of subgingivally delivered 0.5% azithromycin in the treatment of chronic periodontitis[J]. J Periodontol, 2008, 79(11): 2125-2135. [28] Pradeep AR, Bajaj P, Agarwal E, et al.Local drug delivery of 0.5% azithromycin in the treatment of chronic periodontitis among smokers[J]. Aust Dent J, 2013, 58(1): 34-40. [29] Venkatesh MP, Kumar T, Avinash B, et al.Development, in vitro and in vivo evaluation of novel injectable smart gels of azithromycin for chronic periodontitis[J]. Curr Drug Deliv, 2013, 10(2): 188-197. [30] 王颖, 铖谣, 李景坤, 等. 阿奇霉素对人牙周膜干细胞成骨分化能力影响的初步研究[C]. 大连: 2016国际口腔及颅颌前沿研究研讨会暨全国口腔生物医学年会, 2016: 2. |